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Abstract
Gut microbiota (GM) in the epigenetic mechanisms of diabetes mellitus and the repro-
gramming of the cells is a novel and emerging concept. The purpose of this chapter is 
to describe the modification of the GM and its relation with DM2. The increased risk 
of this disease is associated with changes in the amount of Bacteroides/Clostridium in the 
Firmicutes/Bacteroidetes ratio of people having DM. A dysbiosis state associated gener-
ates low-grade inflammation with similar characteristics that occur under metabolic 
syndrome, whose pattern is recognized by Toll-like receptor that recognizes important 
patterns of immunity. The synthesis of butyrate generated by intestinal microorganisms 
inhibits the metabolic pathway of histone deacetylase, promoting cellular differentiation, 
proliferation, and insulin resistance. On the other hand, the direct relationship between 
the neuroendocrine system and the GM has been demonstrated through the production 
of serotonin by enterochromaffin cells, whose action could influence the etiopathogenic 
factors of DM2.
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1. Introduction
Diabetes mellitus type 2 (DM2) is a global pandemic; although genetic factors can predis-
pose subjects to suffer from it, external factors such as socioeconomic changes and cultural 
and eating habit changes have more contributions to increasing world prevalence [1], where 
overweight and obesity are considered as the main mediators of the disease. The number 
of cases of DM2 according to the International Diabetes Federation is 415 million adults by 
2015. The risk death of subjects with DM is significantly higher than those without the dis-
ease, doubling it when we refer to cardiovascular death reason [2]. It has been determined 
that the gut microbiota (GM) is altered in subjects with type 2 diabetes, so studying its role 
in the development of pathology is essential to determine new approaches to treatment; it 
permits the identification of those bacteria beneficial to humans, from the bacterial genome 
recognition. The so-called microbiome correspond to the entire GM genome; it exceeds the 
size of the human genome, having about 500 times more genes that complement our coding; 
this bacterial ecosystem has evolved in a symbiotic relationship with human [3]; GM exerts 
nutritional, metabolic, and immunological functions that affect the human being. During the 
last decade, several studies have been reported on the effect of the GM on glycemic control 
[4]. In this context, GM in the epigenetic mechanisms of diabetes mellitus and the repro-
gramming of the cells is a novel and emerging concept. It is known that products derived 
from diet along with intestinal bacteria can change the epigenome of the host with favorable 
metabolic effects [5]. These microorganisms are essential for the biosynthesis of vitamins 
and hormones, as well as for the degradation of nondigestible dietary fibers and mucin in 
simple sugars and short-chain fatty acids [6]. Changes in the composition and function of the 
predominant GM are associated with an increased risk of DM2 and are linked to an increase 
in the number of Bacteroides [7] and Clostridium [8]. Specifically, the increase of Firmicutes/
Bacteroidetes ratio in the distal bowel, as well as the number of opportunistic pathogens, and 
in the production of endotoxins of Gram-negative bacteria is capable of modifying intestinal 
permeability. The metabolic syndrome is associated with changes in the framework of the 
GM that lead to low-grade inflammations, since the increased permeability of the intesti-
nal membrane damaged by bacteria induces inflammation, through the epigenetic altera-
tion of inflammatory molecules such as Toll-like receptors [9]. Mucus and glycocalyx layer 
mainly produced by Bacteroides thetaiotaomicron, Akkermansia muciniphila, and Escherichia coli 
cause chronic low-level inflammation, insulin resistance, and, lastly, DM2 [10]. Evidence 
demonstrates the link between diabetes and histone deacetylase (HDA), because the micro-
organisms producing butyrate, an HDA inhibitory molecule that promotes differentiation 
and cellular proliferation and insulin resistance [11], are decreased in diabetics [5]. On the 
other hand, it has been recognized that the microbiome has a direct effect on the immune 
and neuroendocrine system, constituting a new brain gut axis [12], in which the circadian 
rhythm plays a fundamental role [13]. The production of colonic serotonin [14, 15] by the 
microbiome, through the effect of short-chain fatty acids on enterochromaffin cells [13, 16, 
17], would allow to relate this neurotransmitter to the metabolic processes as one of the 
possible etiopathogenic factors of DM2. The next challenges are focused on integrating the 
transcriptomic, epigenetic, proteomic, and metabolic information of the human genome and 
the microbiome into the nutritional treatment [2].
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2. Microbiome, epigenetics, and diabetes interactions (metabolic 
pathways)
The human intestinal microbiota (HIM) is composed of a complex community of microorgan-
isms; more than 1000 species have been identified, where only a few are cultivable [18]. The 
gut microbiome corresponds to a total set of genes present in the HIM (about 3 million genes), 
approximately 150-fold human genome [19]. This microorganism participates as a counterpart 
of gut enzymatic activities by a diverse metabolic repertoire becoming an important contributor 
to the metabolism of the host [20]. Exploratory studies have been shown that play an important 
role in the etiology and development of many diseases, being considered as markers of the 
course of the disease. Some chronic illnesses in which HIM has been regarded are the inflam-
matory bowel disease (IBD), the irritable bowel syndrome (IBS), diarrhea, obesity, diabetes, 
and inclusive cancer. The recent role attributed to the microbiome and health has promoted the 
research to study the microorganism characteristics and the design of strategies to restore dam-
age microbiome to a normal “state” by using a microbe inoculation strategy or by using dietary 
modification to feed specific species and help their development or otherwise consume foods or 
other substances that induce the extinguishment of some species in the intestine. The abundance 
and diversity of the intestinal bacteria are located mainly in the large intestine where it exerts 
its principal metabolic role. Bacteria are capable of hydrolyzing carbohydrates, lipids, and pro-
teins principally; saccharolytic bacterial fermentation produces generally beneficial metabolites 
such as short-chain fatty acids (SCFAs) and gases. The three most abundant SCFAs detected in 
feces are acetate, propionate, and butyrate, in molar ratios of 3:1:1 to 10:2:1 [21]. Butyrate is rec-
ognized as the most important SCFA for human health and is absorbed by the epithelial cell of 
the colon in the proximal colon via passive diffusion and by active transport mechanisms. Some 
properties have been attributed to butyrate, for instance, being able to be used by colonocytes as 
energy source, the potential anticancer activity inducing apoptosis of colon cancer cells, its abil-
ity to regulate gene expression in host by inhibiting histone deacetylases [22], and the beneficial 
effects in glucose regulation by activation of gluconeogenesis in the gut via cAMP-dependent 
manner [23].On the other hand, propionate exerts a dual action in intestine and liver regula-
tion of gluconeogenesis and is considered an important molecule for satiety signaling because 
of an interaction with G protein-coupled receptors GPR 41, GPR 43 receptors, and fatty acid 
receptors FFAR2 and FFAR3. The net effect of the conversion of propionate to glucose is the 
decrease of gluconeogenesis in the liver; this generates a reduction in the production of adipos-
ity [23]. Acetate is the most abundant SCFA and is considered as essential metabolite for bacteria 
growth. Faecalibacterium prausnitzii will not grow in pure culture in the absence of acetate [24]. 
Acetate participates in the cholesterol metabolism and lipogenesis in the host [25].
2.1. Microbiota metabolism
A cross-feeding effect has recently been described, for instance, Bifidobacterium longum growing 
in fructooligosaccharides (FOS) produces a conversion into lactate and promotes the growth of 
Eubacterium hallii that could not grow in the presence of FOS alone and converts it to butyrate [26]. 
Another example of cross feeding occurs when Roseburia intestinalis increases its growth in 
co-cultures with—the acetate contributor—B. longum [27, 28]. Two main routes of butyrate 
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 production [29] and three pathways for propionate production have been identified in bacteria; 
noteworthy peptide and amino acid can be used to form propionate and butyrate from some 
species of Bacteroidetes and Firmicutes. The main sources of propionate are aspartate, alanine, 
threonine and methionine, instead glutamate, lysine, histidine, cysteine, serine and methionine 
for butyrate production [30]. Sequencing targeted gene instead of 16S rRNA genes indicates 
that most bacteria had the capability to produce exclusively propionate or butyrate but not 
both. Conversely, bacteria change their fermentation depending on growth conditions and 
produce different SCFAs. Roseburia inulinivorans produces butyrate normally, but it can change 
its gene expression pattern in the presence of fucose producing propionate and propanol [31]. 
Ruminococcus obeum produces acetate, formate, and lactate on glucose growth and also pro-
duces propionate in the presence of fucose. Bacteroides thetaiotaomicron in the presence of fucose 
also increases fucosylated glycan to be used in absence of nutrients; it has been described that 
it is also important in early colonization of the infant gut [32]. By decreasing the carbohydrate 
content of the diet significantly reduced both fecal butyrate concentrations and numbers of the 
Roseburia/E. rectale group [33]; wheat bran has >70% arabinoxylan oligosaccharides (AXOS) 
that increase the SCFA content [34]. Unfortunately, the increased SCFA content causes reduced 
transit time and thus a decreased colonic absorption of SCFA. Excluding those vegetables rich 
in short fermentable carbohydrates such as oligosaccharides, monosaccharides, and polyol 
(FODMAP diet) reduces bacterial fermentation, showing a decrease in the total numbers of 
bacteria, and the fecal concentration of different SCFAs is similar to the control diet [35].
2.2. Gas production and the microbiome
HIM generates hydrogen, carbon dioxide, and methane, all of them odorless gases; odoriferous 
gases constitute less than 1% of total flatus and include NH
3
, hydrogen sulfide, indole, skatole, 
and volatile amines. There are many bacteria that do not produce gas [36] such as lactobacilli 
and bifidobacteria, so they can be used as probiotic able to reduce the gas content in colon. 
Gases can be excreted by flatus (several liters per day in a healthy human) [37]. Hydrogen 
is produced by Bacteroides and Clostridium [38] and produces a high energy yield, and it can 
be used by other bacteria from the gut to produce lactate, succinate, and ethanol and sulfate-
reducing bacteria (SRB), where Desulfovibrio is the principal [39]. In the methanogenesis CO2 is converted to CH4, and in the acetogenesis dioxide and hydrogen are converted into acetate both use hydrogen [38]. Carbon dioxide is between 5 and 50% of the total flatus volume, and 
it is produced by acidification of bicarbonate in the upper gastrointestinal tract, and bacterial 
metabolism [40], C. sporogenes, C. butyricum, and C. perfringens, produces hydrogen and CO2.
2.3. Proteins
HIM has an important role converting protein metabolism, enzymes, mucin in short peptides, 
fatty acids and gases (H2, NH4, CO2 and H2S), Clostridia, Streptococci, Staphylococci, Bacillus 
and species of Bacteroides and Propionibacterium as the predominant proteolytic characteristics 
in fecal samples [41]. A preference for amino acid fermentation at higher ranges of colonic pH 
and a reduction in quantity when fermentable carbohydrate was available are observed [42]. 
The proximal colon was predominantly saccharolytic by nature; whereas protein fermenta-
tion increased distally, the fermentation was associated with the presence of phenol, indole, 
ammonia, and branched-chain fatty acids [21]. Aromatic amino acids phenylalanine, tyrosine, 
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and tryptophan can be fermented to phenylpropanoid, phenylacetic acid, and 4-hydroxyphe-
nyl-acetic acid by Bacteroides, Eubacterium hallii, and Clostridium bartlettii [43].
2.4. Vitamin synthesis and the microbiome
Gut microbiome can synthesize certain vitamins, such as vitamin K, biotin, cobalamin, folates, 
nicotinic acid, pantothenic acid, pyridoxine, riboflavin, and thiamine of B group [44]. For 
instance, subjects having low vitamin K diet showed an important decrease in plasma pro-
thrombin when treated with broad-spectrum antibiotic [45]. Explored genomes in gut showed 
presence of eight vitamin B synthesis pathways. The most represented were riboflavin [46] 
and niacin with 162 genomes. Bacteroidetes is the phylum with larger B predicted vitamin gen-
erators. In the same line, bacteria can complement the biosynthesis of vitamins. In sum, GM 
can contribute with 25% of total dietary vitamin intake [47].
2.5. Bile acids and the microbiome
Gut microbiota can modify the structure of bile acid in the colon, because bile acids have anti-
microbial activity causing membranes and DNA damage [48]. Deoxycholic acid produced by 
microorganisms is tenfold greater than cholic acid producing a feedback to control bacteria 
population [49]. Bile salt hydrolase enzyme has been recognized in Bacteroides, Bifidobacterium, 
Clostridium, Lactobacillus, and Listeria [50]. It can deconjugate bile acids reducing its toxicity 
[51]. Microbial dehydroxylation by Clostridium and Eubacterium transforms chenodeoxycholic 
acid and cholic acid into lithocholic acid and deoxycholic acid, it can produce a cytotoxic 
effect on enterocytes, and it can be associated with colon cancer. On the other hand, bile 
acids are also a ligand for nuclear receptor farnesoid X receptor (FXR) and plasma membrane-
bound GPR TGR [52] that regulates their synthesis and affects the lipid and glucose metabo-
lism [53]. Bacteria deconjugate bile acids reducing the efficacy of lipid emulsification showing 
a downstream effect in metabolic processes.
2.6. Gut microbiota and diabetes type 2
Diet plays an important role in obesity. There are preliminary studies suggesting that the con-
sumption of probiotic bacteria found in yogurt and other fermented milk products can benefi-
cially alter the composition of the gut microbiome. Yogurt, a fermented dairy product containing 
a variety of probiotic bacteria, is found to be associated with a reduction in inflammation mark-
ers and weight loss [54]. Yogurt consumption is involved in energy balance and/or energy 
homeostasis, which in turn controls body weight and reduces the risk of the development of 
DM2 [55]. One of the causes of dysbiosis is diet, and studies have shown that diet may change 
the gut microbiota and contribute to obesity and diabetes [56]. Obesity and DM2 are charac-
terized by an altered gut microbiota, inflammation, and gut barrier disruption [57]. Studies in 
germ-free animals have shown that shifts in the composition of the gut microbiome may play an 
important role in disease development, specifically obesity and diabetes [58]. There is evidence 
demonstrating that the composition of the gut microbiota also influences metabolism and can 
affect energy balance [59], gut permeability [60], and inflammation [61], all of which are associ-
ated with obesity and associated disorders, including DM2 [62]. The evidence for the role of the 
HIM in metabolism of dietary components and the impact on health has been obtained from 
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comparative studies in germ-free animals, by using conventional microbiome, or by animals 
with human microbiome-associated, and from in vitro studies using human fecal incubations. In 
this sense, gastric bypass surgery leads to a substantial shift in the gut microbiota, which may 
contribute to weight loss in part by HIM modifications [63]. One of the most important situa-
tions is that the immune system faces microbiome continuously and it affects the host immunity 
and inflammation control. In this line, GM can affect the immune system by metabolites like 
SCFAs [64] and toxin production, such as LPS [61], modifying the adipogenesis and influence 
in the insulin resistance. LPS induces generation of pro-inflammatory cytokines by the immune 
system and adipocytes. Acetate, butyrate, and propionate (SCFA) modulate the gene expression 
in host, modifying the infant microbiome and stimulating white blood cells [65]. Some studies 
suggested that infants born by cesarean section are at greater risk of developing obesity and/
or diabetes than those born vaginally [66]. Other studies with preschool children showed over-
weight or obesity in children born by cesarean [67], while in other showed the opposite [68]. On 
the other hand, infant feeding is also important to develop GM because mother milk is not sterile 
and is the first bacteria to colonize the gut [69]. Breast milk is a source of probiotics and other 
bacteria [71] containing more than 700 species [70]. The median bacterial load is 106 bacterial 
cells/Ml [71]. Streptococci and Staphylococci are predominant bacterial genera in human milk [69]. 
Weissella, Leuconostoc, Staphylococcus, Streptococcus, and Lactococcus are predominant in colos-
trum and are thought to modify the lactation to increase Veillonella, Leptotrichia, and Prevotella 
for over 6 months [71]. In this line, milk from obese mothers contains less-diverse bacteria than 
normal-weight mothers and has pro-inflammatory properties [72, 73, 74]. Another import issue 
is the infection of virus or bacteria pathogens. For instance, Clostridium difficile patients and 
asymptomatic carriers with the use of 16S ribosomal RNA gene pyrosequencing found that both 
had reduced microbial richness, diversity, and dysbiosis state compared with healthy subjects 
[75]. Gut microbiota transplants can help to increase the richness and diversity of GM [76]. For 
example, clearance of hepatitis B virus infection requires the reestablishment of the gut micro-
biota. Drugs also affect the microbiome including the drugs used to treat DM2 [77]. But also 
in the opposite direction. Broad-spectrum antibiotics reduce bacterial diversity and provoke 
the augmentation of some species like opportunistic pathogens [78], predisposing to inflam-
matory bowel disease [79]. Clindamycin produces a prolonged effect of modifying the micro-
biome in infants [80]. Studies in both mice and humans have found that the use of antibiotics 
early in life could promote obesity later in life, mediated by the alteration of the gut microbiota 
[81]. In the same line, antibiotics can reduce body weight and increase insulin sensitivity [82]. 
Berberine is recognized for its antidiabetic effect by modulating the gut microbiota and diminish-
ing glucose and insulin resistance [83]. Metformin increases the insulin sensitivity in fat cells 
and hepatocytes and also reduces the overproduction of glucose in hepatocytes. Recent studies 
showed that metformin alters the GM [84, 85]. In obese mice, metformin caused the increase of 
mucin-degrading Akkermansia [85]. In human GM, altered gut microbiota can be the cause of 
common metformin side effects and could have a role in drug efficacy. There is a link between 
high-calorie diets contributing to obesity and DM2 and GM [55]. Dietary changes can result in 
substantial and rapid changes in the GM [86]. High-fat diet reduces the α diversity in GM. For 
instance, A. muciniphila decreased in obese mice and DM2, and it can be normalized by prebiotic 
consumption [62]. Treatments with A. muciniphila reduced fat mass, inflammation, and insulin 
resistance induced/caused by high-fat diet [62]. An enterotype is a classification of living organ-
isms based on their bacteriological ecosystem in the gut microbiome. Changes in GM entero-
types were strongly associated with long-term diets, Bacteroides with protein and animal fat, and 
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Prevotella with carbohydrates; gut microbiota composition depends on diseases and long-term 
dietary interventions. GM alterations can be observed within 24 h after high-fat and low-fiber or 
low-fat and high-fiber diet [87]. Type 1 is characterized by high levels of Bacteroides, type 2 has 
few Bacteroides but Prevotella are common, and type 3 has high levels of Ruminococcus [18].
3. Metagenomic, metatranscriptomic, metaproteomic, and 
metabolomic approaches to mimic the gut ecosystem
Metagenomics is used to study differences in microbiome composition having diseases and 
compared with healthy people. Recently a technique was developed (Ecemble; enzyme clas-
sification using ensemble approach) to predict enzymes from protein sequences in gut microbi-
ome from metagenomic samples and study the role of GM in metabolism; 48 pathways having 
at least one bacteria-encoded enzyme were found [88]. The carbohydrate active enzymes are 
important due to their role in dietary fiber and non-absorbed carbohydrate metabolism; 81 fami-
lies of glycoside hydrolases have been identified. On the other hand, single-cell genomics uses 
isolated colonies to shotgun sequencing and put in phylogenetic context to complement metage-
nomic analysis. Is important to note that the presence of a gene does not mean it amounts to their 
expression; in this sense, metatranscriptomics, metaproteomics, and metabonomics are needed. 
Metatranscriptomics involves the generation of cDNA by reverse transcription and permits to 
identify noncoding RNAs and small RNAs that control quorum sensing and stress response 
[89]. Metatranscriptomics of fecal microbiome analysis of the 16S rRNA transcripts showed 
Firmicutes (49%) and Bacteroidetes (31%) are the main source of RNA and smaller proportion 
of Proteobacteria (3.7%), Actinobacteria (0.4%), and Lentisphaerae (0.2%) and Lachnospiraceae and 
Ruminococcaceae are the major proportion of Firmicutes, whereas Bacteroidaceae, Prevotellaceae, and 
Rikenellaceae for Bacteroidetes phylum [90]. Other transcripts were compared with COG database 
to obtain a functional distribution. Results showed similar behavior for carbohydrate transport, 
energy production, and synthesis of cellular components. Nevertheless acid and lipid metabo-
lism, motibily, and secondary metabolite biosynthesis were underregulated. Unfortunately, 
short half time of bacteria RNA makes the detection of all RNAs in fecal samples difficult. 
Metaproteomics permits to determine gene translation and post-transductional modifications 
and permits to classify microorganism to a specific catalytic function [91, 92]. Temporal stabil-
ity of the fecal metaproteome was assessed, and it was determined that glutamate dehydroge-
nase showed high level of redundancy in Lachnospiraceae, Bacteroidaceae, Ruminococcaceae, and 
Bifidobacteriaceae. Ten percent of total proteome is involved to ABC sugar transport and glycolytic 
enzymes; the main functional categories were metabolism of carbohydrates, nucleotides, energy, 
amino acids, and cofactors and vitamins (especially B12 and folic acid) [87]. Finally, metabolo-
mic approach allows to determine low-molecular-weight compounds in fecal sample and can be 
influenced by environmental inputs and metabolic interactions between host and environment. 
For example, SCFA content in the gut can be modified by diet; after that, absorption from the gut 
initiates the metabolism of the host and results in downstream metabolic perturbations and the 
generation of microbial-host co-metabolites [93]. For instance, intake of choline (meat and eggs) 
can form trimethylamine and dimethylamine by GM, trimethylamine is toxic and should be con-
verted to trimethylamine-N-oxide (TMAO), and the latter is an electron acceptor for  anaerobic 
 metabolism of E. coli and is implicated in cardiovascular disease (CVD) [94–98]. Genomic 
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 analyses of the GM of subjects suffering from DM2 allowed to identify bacterial genes that are 
differentially expressed in those subjects; these changes in the gene expression of microbiome 
are related to the metabolic dysfunction and inflammation that these patients suffer from [99]. 
Bacterial genes including Clostridiales sp. SS3/4, Faecalibacterium prausnitzii, Roseburia intestinalis, 
and Roseburia inulinivorans are decreased in patients with DM2, whereas genes corresponding to 
Bacteroides sp., Clostridium hathewayi, Clostridium ramosum, Clostridium symbiosum, and Eggerthella 
lenta, are increased in these subjects [100]. Functional analyses suggest enriched genes in samples 
of DM2 patients are involved in plasmatic membrane sugar transport, branched-chain amino 
acids transport, methane metabolism, xenobiotic degradation and metabolism, biosynthesis of 
hydrogen sulfide, and oxidative stress. In contrast, decreased genes are related to functions such 
as chemotaxis, flagellum assembly, butyrate biosynthesis, and the metabolism of cofactors and 
vitamins [100]. The depletion of bacterial strains producing butyrate in patients with DM2 may 
be related to the ability of this fatty acid to increase secretion of peptide similar to glucagon type 
1 (GLP1) and peptide YY, whose function is to promote intestinal gluconeogenesis, which leads 
to a better control of glucose homeostasis and cellular energy (Figure 1) [101, 102].
4. Nutrigenomics and the microbiome
In most chronic pathologies, environmental and genetic factors are involved because of a 
polygenic behavior. Recent research investigate the mechanisms involved in the dysfunction 
of a healthy phenotype to another with chronic dysfunction, explaining how gene  expression 
Figure 1. Changes in the composition of the gut microbiome are associated with an increased risk of DM2: In patients 
with DM2, the intestinal dysbiosis causes a decrease of short-chain fatty acid content, molecules that stimulate the 
secretion of peptide similar to glucagon type 1 (GLP1) and YY peptide by intestinal cells, proteins that control glucose 
homeostasis and regulate the intake of nutrients in intestinal cells.
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and dietary components regulate genetic information. Nutrigenomics involves understand-
ing how diet components affect gene expression, meaning which genes are induced and 
which are repressed against a particular nutrient [103]. Chronic diseases, such as obesity, 
DM2, and cancer, are expressed from complex polygenic reactions with the environment. The 
most influential environmental interaction in the development of these diseases is given by 
the consumed nutrients. Evidence of gene-nutrient interaction is substantially demonstrated, 
estimating that a balanced healthy nutrition reduces the overall incidence of cancer by 35%. 
On the other hand, polymorphisms that predispose to certain diseases have been identified 
under unhealthy diet; this is the case of DM2, osteoporosis, vascular disease, and others, 
which can be prevented by modifying the diet [104]. The regulation of gene expression is 
performed through specific proteins that interact with DNA through posttranscriptional or 
posttranslational modifications. Regulation can occur at the level of mRNA during splicing; 
it would result from the interaction of certain molecules with specific nutrients, whose result 
could be potentially preventive [104]. The diet and the GM composition have also been asso-
ciated with different characteristics of the metabolic syndrome (MS) (obesity, DM2, cardio-
vascular diseases, and nonalcoholic steatohepatitis). Increasing evidence suggests that the 
GM contributes to the onset of its characteristic low-grade inflammation, through mecha-
nisms associated with intestinal barrier dysfunction [105]. The GM of an obese person in 
comparison with a normal-weight person presents a greater percentage of Firmicutes and 
smaller percentage of Bacteroidetes, causing dysbiosis in most of the obese and/or diabetic 
patients (Figure 2). Due to its physiological impact, GM is now recognized as an organ and 
can be transplanted from one individual to another [106]. Recent evidence suggests that the 
intestinal  microbiome affects nutrient acquisition, energy storage, and metabolic pathways 
of the host [10]. Bacteroidetes have been shown to easily assimilate dietary carbohydrates. 
In a study in mice lacking Toll-like receptors (TLRs), which are receptors that recognize 
important patterns of inflammation and immunity, it is shown that these mice present hyper-
phagia and obesity and develop metabolic syndrome, when intestinal microbiome of these 
Figure 2. The GM of an obese person in comparison with a normal-weight person presents a greater percentage of 
Firmicutes and smaller percentage of Bacteroidetes, causing dysbiosis in most of the obese and/or diabetic patients.
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mice is transplanted to germ-free mice with the TLR5 gene intact; they also developed the 
Bifidobacterium strain similar to the metabolic syndrome, suggesting that the GM was the 
determinant factor of this disease phenotype [107]. Another study showed that mice deficient 
in TLR2 presented greater amount of Firmicutes and Actinobacteria and smaller amount of the 
genus Bifidobacterium [10, 107]. Administration of an antibiotic cocktail eliminated many of 
the Firmicutes and resulted in improved insulin action and increased glucose tolerance [107].
5. New brain gut axis, serotonin production, and its relationship 
with DM
Some studies have shown the clear connection between immune system and neuroendocrine 
system highlighting the effect of the GM, which allows a new focus for research on the so-called 
brain gut axis [12]. The mechanisms of enteric neuroprotection were recently been described; 
enteric neurons have one of their own signaling molecules to this propose. In the adult intes-
tine, serotonin acts like a paracrine signal hormone and neurotransmitter [108]. However, it 
is also a neuronal growth factor during development and a major promoter of mucosal epi-
thelium growth by stimulating submucosal cholinergic neurons [109]. This neurotransmitter 
may even stimulate neurogenesis in the growing enteric nervous system, and in adults, this 
hormone promotes neurogenesis and neuroprotection through the activation of 5-HT4 recep-
tors. It is interesting to mention that mucosal serotonin is not a direct neuroprotective agent to 
enteric neurons. Mucosal serotonin behaves as a pro-inflammatory factor, and this ability con-
stitutes a threat to neuronal survival [110]. According to these facts, this hormone has received 
the name of “sword and shield” of the intestine. Mucosal serotonin is the pro-inflammatory 
“sword,” while neuronal serotonin is the anti-inflammatory “shield” [111]. It has been demon-
strate that DM1 is related with an excess of pro-inflammatory cytokines close to B pancreatic 
cells, while DM2 is caused due to an excess of pro-inflammatory cytokines in systemic circula-
tion, which could be related to intestinal serotonin secretion. Gershon et al. have established 
that neurodegenerative/neuroprotective actions of 5-HT4 receptor complex may be vital for the 
normal enteric nervous system’s maintenance [12]. Bianco et al. show the mechanisms through 
the 5-HT4 agonist participate in protection of enteric neurons against oxidation [112]. This sen-
tence is relevant because the enteric neurons lost during inflammation strongly depend on the 
released forces throughout oxidative stress (Figure 3) [113, 114]. Bhattarai et al. suggest that the 
“sword” function is manipulated by the microbiome [115]. The intestine has a variety of regu-
latory mechanisms that contrast the actions of 5-HT for transport maintenance; conversely, 
Chang and Rao incorporate the GM as a homeostasis influence factor evading the alteration of 
5-HT during diarrhea and intestine inflammatory diseases. Recently, observations have been 
made about the possible mechanisms by which dysbiosis of the microbiome alters the function 
of 5-HT [14]. The HIM plays a key role in enhancing the serotonin biosynthesis in enterochro-
maffin cells. This increased serotonin content stimulates the intrinsic projections of the primary 
afferent neurons and in turn activates interneurons, which activate the peristaltic reflex pro-
moting intestinal motility and besides accelerate the gastric emptying, which is augmented 
when 5-HT receptor is antagonized [111]. The intestinal speedup promotes the production 
of several gastrointestinal hormone secretions that mediate glucose metabolism, unleashing 
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insulin synthesis such as β-cell proliferation or glucagon release [116]. On the other hand, it 
has been shown that serotonin participates during lactate signaling cascade to stimulate β-cell 
proliferation [117]. Under this premise, there is a hypothesis of a possible relation between the 
alteration of the GM by serotonin and the metabolic pathway that generates insulin resistance, 
and it could be considered as one of the possible etiopathogenic factors of DM2.
6. Conclusions
The interaction of the diet in the modification of HIM, in addition to its potential effect on the 
microbiome and the development of DM, has been positively affected by the evolution of nutrig-
enomics as a science discipline. Diets rich in carbohydrates and fats, favor the development of 
bacteria capable of causing intestinal dysbiosis of low degree of inflammation; affecting the per-
meability of the intestinal mucosa. It has been shown that intestinal production of serotonin by 
enterochromaffin cells participates in the cascade of stimulation of the proliferation of pancre-
atic β cells, via the lactate pathway, suggesting the hypothesis of a possible link between sero-
tonin, insulin resistance, and DM2. Finally, the advances reflected in this chapter demonstrate a 
small part of the future projection around nutrigenomics and its effect on the composition of the 
Figure 3. The hypothesis of the alteration of the GM by serotonin and the metabolic pathway 
that generates insulin resistance it could be considered as one of the possible etiopathogenic 
factors of DM2.
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microbiome in diabetic subjects; it would be interesting to carry out more specific studies of this 
area, associating it with the effect of satiety and the alteration of the microbiome in patients with 
obesity and/or metabolic syndrome, as an integral part in the prevention of DM2.
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